BioSpace

MARCH 2, 2021

GE Research selected DNA Script to join a collaboration working on a rapid response, mobile platform to develop on-demand production of nucleic acid-based vaccines and therapies related to biological threats.

DNA 96

DNA Production Vaccination Vaccine 96

BioSpace

APRIL 14, 2021

Shares of Inovio are climbing in early trading this morning after the company announced its DNA vaccine candidate for COVID-19 induced a robust T-cell response against multiple variants of the SARS-CoV-2 virus.

DNA 95

DNA Vaccination Vaccine 95

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Coronavirus vaccine components. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Flavivirus vaccine components. Sanofi is one of the leading patent filers for Flavivirus vaccine components.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

BioSpace

OCTOBER 31, 2021

Inovio shares are down about 2% in premarket trading after cancellation reports of a DNA cancer vaccine collab with AstraZeneca.

DNA 83

DNA Vaccination Vaccine 83

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Multivalent veterinary vaccines. These vaccines are composed of active ingredients (antigens) and other adjuvants, inactivators, preservatives and excipients.

Vaccination 130

Vaccination Vaccine Antibody DNA 130

BioPharma Reporter

AUGUST 27, 2020

million) to move pan-coronavirus synthetic DNA vaccine toward human testing. UK government provides Â1.9 million ($2.5

Vaccination 105

Vaccination Vaccine DNA Regulation 105

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.

Drug Delivery 147

Drug Delivery Vaccination Vaccine Research 147

BioSpace

SEPTEMBER 2, 2021

Celsion announced results from its PLACCINE DNA vaccine platform that showed it produced antibodies and cytotoxic T-cell response specific to the spike antigen of SARS-CoV-2.

DNA 73

DNA Vaccination Vaccine Antibody 73

BioPharma Reporter

FEBRUARY 17, 2022

Start-up biotech Alvea has started pre-clinical testing for its DNA vaccine: with clinical trials set to begin as soon as March.

DNA 75

DNA Vaccination Vaccine Clinical Trials 75

BioPharma Reporter

FEBRUARY 13, 2023

Scancell has reported preliminary immunogenicity data from its Phase 1 COVIDITY clinical trial: with the plasmid DNA based COVID-19 vaccine candidates inducing immune responses when delivered via needle-free tech.

Immune Response 96

Immune Response Vaccination Vaccine DNA 96

pharmaphorum

FEBRUARY 22, 2021

Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year. In December interim phase 1/2 trial results showed the vaccine produced a lower immune response in older adults.

Vaccination 89

Vaccination Vaccine Recombinant DNA Technology Trials 89

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

XTalks

NOVEMBER 23, 2021

Canadian pharma and biotech contract development and manufacturing organization (CDMO) Biovectra has announced plans for building one of the first state-of-the-art mRNA vaccine and biomanufacturing facilities in Canada. Related: Medicago’s Plant-Based COVID-19 Vaccine Enters Human Trials. million, respectively.

Manufacturing 98

Manufacturing Vaccination Vaccine Drugs 98

Scienmag

OCTOBER 30, 2020

Vaccine protects animals against tick-borne Powassan virus, an emerging infectious disease Credit: The Wistar Institute PHILADELPHIA — (Oct. A rapidly reemerging tick-borne disease, POWV has been reported […].

DNA 61

DNA Vaccination Vaccine Protein 61

Scienmag

APRIL 22, 2021

Dose-sparing regimens and intradermal delivery have important implication for rapid clinical development of effective, well-tolerated and easy-to-distribute vaccines against MERS and other emerging coronaviruses.

DNA 61

DNA Vaccination Vaccine Immune Response 61

Scienmag

MARCH 15, 2021

The first vaccine has been administered in a comparative adjuvant trial of DNA prime/protein boost HIV vaccine regimens in Kericho, Kenya Credit: U.S. Military HIV Research Program SILVER SPRING, Md.

Vaccination 68

Vaccination Vaccine Trials DNA 68

BioTech 365

FEBRUARY 12, 2021

United States Travel Vaccines Market Research Report 2021: Focus on Attenuated Vaccines, Conjugate Vaccines, DNA Vaccines, Inactive Vaccines, and Recombinant Vector Vaccines – ResearchAndMarkets.com United States Travel Vaccines Market Research Report 2021: Focus on Attenuated Vaccines, Conjugate Vaccines, DNA Vaccines, … Continue reading (..)

DNA 40

DNA Vaccination Vaccine Marketing 40

BioTech 365

APRIL 27, 2021

PharmaJet Presents Needle-free Delivery of COVID-19 DNA Vaccine Results at World Vaccine Congress PharmaJet Presents Needle-free Delivery of COVID-19 DNA Vaccine Results at World Vaccine Congress Superior immunogenicity cited with Needle-free delivery GOLDEN, Colo.–(BUSINESS

DNA 40

DNA Vaccination Vaccine 40

pharmaphorum

OCTOBER 2, 2020

Roche’s Genentech unit has paid $200 million to develop an individualised cancer vaccine with Norwegian biotech Vaccibody, which focuses on targets known as neoantigens that spring up as tumours grow and mutate. Frame Therapeutics has also begun work on neoantigen-based cancer vaccines based on RNA technology.

Vaccination 59

Vaccination Vaccine Immune Response Drugs 59

pharmaphorum

MAY 9, 2022

vaccine to treatment with Roche’s cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer. is the lead candidate using its Vaccibody technology, designed to generate DNA plasmids directed against neoantigens that are only found on tumour cells. A phase 1b trial of VB10.NEO

Vaccination 64

Vaccination Vaccine Trials DNA 64

Pharmaceutical Commerce

AUGUST 21, 2024

Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.

Vaccination 52

Vaccination Vaccine DNA Clinical Trials 52

BioTech 365

SEPTEMBER 17, 2021

Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine Expands GEN-1 Program Collaboration to Add Clinical and Commercial Batches of Investigational Vaccine LAWRENCEVILLE, N.J.

DNA 40

DNA Manufacturing Vaccination Vaccine 40

pharmaphorum

MARCH 2, 2021

The COVID-19 pandemic brought life-changing disruptions to people around the world and has turned the typical vaccine R&D process on its head. Overcome immunogenicity challenges and design safe and efficacious vaccine formulations. The post Genetic Vaccine Development for Infectious Diseases Summit appeared first on.

Genetics 52

Genetics Vaccination Vaccine Development 52

BioTech 365

JULY 7, 2021

PharmaJet Partner Zydus Cadila Seeks EUA on World’s First Plasmid DNA COVID-19 Vaccine PharmaJet Partner Zydus Cadila Seeks EUA on World’s First Plasmid DNA COVID-19 Vaccine Vaccine delivered exclusively with the PharmaJet Needle-free System GOLDEN, Colo.–(BUSINESS

DNA 40

DNA Vaccination Vaccine 40

XTalks

FEBRUARY 11, 2021

Amidst growing global shortages of COVID-19 vaccine supplies, inaugural (by way of authorizations/approvals) COVID-19 vaccine maker Pfizer is addressing the issue by working to cut the manufacturing time of its vaccine by almost half. Related: Pharma Rivals Step Up to Assist with COVID-19 Vaccine Production.

Manufacturing 52

Manufacturing Vaccination Vaccine DNA 52

Roots Analysis

MARCH 16, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA. It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein.

Vaccination 52

Vaccination Vaccine DNA Protein 52

BioTech 365

NOVEMBER 26, 2021

Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea Technology Transfer spanning the complete production process Enzychem shall produce 80 million … Continue reading →

DNA 40

DNA Manufacturing Vaccination Vaccine 40

pharmaphorum

SEPTEMBER 29, 2020

Inovio Pharma’s plan to start pivotal testing of its COVID-19 vaccine has been delayed by FDA requests for more information, sending its shares into a swift decline. Inovio’s vaccine takes the form of a DNA plasmid coding for the full length of the spike or ‘s’ glycoprotein antigen of SARS-CoV-2, the vaccine that causes COVID-19.

Vaccination 52

Vaccination Vaccine Trials DNA 52

The Pharma Data

DECEMBER 20, 2020

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.

Clinical Trials 52

Clinical Trials Clinical Trials Pharma Companies Vaccination 52

The Pharma Data

JANUARY 11, 2021

11, 2021 — As the rollout of the COVID-19 vaccines continues, scores of questions are emerging. How do the COVID-19 vaccines work? The COVID-19 vaccines work by teaching the immune system to protect against the virus, experts said. “That means it never converts into DNA,” Dr. M. MONDAY, Jan.

Vaccination 52

Vaccination Vaccine Allergies Protein 52

BioTech 365

APRIL 12, 2021

Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA™ COVID-19 Vaccine Candidate in Felines Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA™ COVID-19 Vaccine Candidate in Felines … Continue reading →

DNA 40

DNA Clinical Trials Clinical Trials Vaccination 40

BioTech 365

NOVEMBER 5, 2021

Applied DNA and CLEARED4 Offer Fast, Cost-Effective and Turnkey Integrated Solution for Compliance with OSHA Mandate for COVID-19 Vaccination and Testing Applied DNA and CLEARED4 Offer Fast, Cost-Effective and Turnkey Integrated Solution for Compliance with OSHA Mandate for COVID-19 Vaccination … Continue reading →

Compliance 40

Compliance DNA Vaccination Vaccine 40

BioTech 365

APRIL 16, 2021

Aegis Life Announces Start of Phase 1/2 Trial of the Entos COVID-19 DNA Vaccine, Covigenix VAX-001, with First Participants Dosed Aegis Life Announces Start of Phase 1/2 Trial of the Entos COVID-19 DNA Vaccine, Covigenix VAX-001, with First Participants Dosed … Continue reading →

DNA 40

DNA Vaccination Vaccine Trials 40

BioTech 365

SEPTEMBER 15, 2020

.–(BUSINESS WIRE)–PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Stratis® Needle-free Injection System will be used to deliver a novel DNA vaccine against COVID-19 (GX-19) which is being developed by an international consortium led by … Continue reading →

DNA 40

DNA Vaccination Vaccine Development 40

BioTech 365

JUNE 7, 2021

Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, 1.526 Variants and Sets August 2021 Mink Challenge Trial Launch Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in … Continue reading →

DNA 40

DNA Antibody Trials Vaccination 40

BioTech 365

OCTOBER 12, 2021

Celsion Corporation Announces Oral Presentation at International Vaccines Congress Celsion Corporation Announces Oral Presentation at International Vaccines Congress Chief Science Officer Dr. Khursheed Anwer to Deliver Virtual Presentation on Celsion’s Ongoing Work with DNA-based Vaccines LAWRENCEVILLE, N.J.,

Vaccination 40

Vaccination Vaccine DNA 40